Literature DB >> 33711021

Mecamylamine inhibits seizure-like activity in CA1-CA3 hippocampus through antagonism to nicotinic receptors.

Olha Zapukhliak1, Olga Netsyk1, Artur Romanov1, Oleksandr Maximyuk1, Murat Oz2, Gregory L Holmes3, Oleg Krishtal1, Dmytro Isaev1.   

Abstract

Cholinergic modulation of hippocampal network function is implicated in multiple behavioral and cognitive states. Activation of nicotinic and muscarinic acetylcholine receptors affects neuronal excitability, synaptic transmission and rhythmic oscillations in the hippocampus. In this work, we studied the ability of the cholinergic system to sustain hippocampal epileptiform activity independently from glutamate and GABA transmission. Simultaneous CA3 and CA1 field potential recordings were obtained during the perfusion of hippocampal slices with the aCSF containing AMPA, NMDA and GABA receptor antagonists. Under these conditions, spontaneous epileptiform discharges synchronous between CA3 and CA1 were recorded. Epileptiform discharges were blocked by addition of the calcium-channel blocker Cd2+ and disappeared in CA1 after a surgical cut between CA3 and CA1. Cholinergic antagonist mecamylamine abolished CA3-CA1 synchronous epileptiform discharges, while antagonists of α7 and α4β2 nAChRs, MLA and DhβE, had no effect. Our results suggest that activation of nicotinic acetylcholine receptors can sustain CA3-CA1 synchronous epileptiform activity independently from AMPA, NMDA and GABA transmission. In addition, mecamylamine, but not α7 and α4β2 nAChRs antagonists, reduced bicuculline-induced seizure-like activity. The ability of mecamylamine to decrease hippocampal network synchronization might be associated with its therapeutic effects in a wide variety of CNS disorders including addiction, depression and anxiety.

Entities:  

Year:  2021        PMID: 33711021      PMCID: PMC7954330          DOI: 10.1371/journal.pone.0240074

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  34 in total

Review 1.  Brain nicotinic acetylcholine receptors: native subtypes and their relevance.

Authors:  Cecilia Gotti; Michele Zoli; Francesco Clementi
Journal:  Trends Pharmacol Sci       Date:  2006-07-31       Impact factor: 14.819

Review 2.  The generation of theta rhythm in hippocampal formation maintained in vitro.

Authors:  Tomasz Kowalczyk; Renata Bocian; Jan Konopacki
Journal:  Eur J Neurosci       Date:  2012-12-20       Impact factor: 3.386

Review 3.  Nicotinic ACh receptors in the hippocampus: role in excitability and plasticity.

Authors:  Jerrel L Yakel
Journal:  Nicotine Tob Res       Date:  2012-04-03       Impact factor: 4.244

4.  Conditions sufficient for nonsynaptic epileptogenesis in the CA1 region of hippocampal slices.

Authors:  Marom Bikson; Scott C Baraban; Dominique M Durand
Journal:  J Neurophysiol       Date:  2002-01       Impact factor: 2.714

5.  Properties of carbachol-induced oscillatory activity in rat hippocampus.

Authors:  J H Williams; J A Kauer
Journal:  J Neurophysiol       Date:  1997-11       Impact factor: 2.714

Review 6.  Cholinergic modulation of the hippocampal region and memory function.

Authors:  Juhee Haam; Jerrel L Yakel
Journal:  J Neurochem       Date:  2017-08       Impact factor: 5.372

Review 7.  Mammalian nicotinic acetylcholine receptors: from structure to function.

Authors:  Edson X Albuquerque; Edna F R Pereira; Manickavasagom Alkondon; Scott W Rogers
Journal:  Physiol Rev       Date:  2009-01       Impact factor: 37.312

Review 8.  Neuromodulation of brain states.

Authors:  Seung-Hee Lee; Yang Dan
Journal:  Neuron       Date:  2012-10-04       Impact factor: 17.173

9.  Cholinergic modulation of hippocampal network function.

Authors:  Leonor M Teles-Grilo Ruivo; Jack R Mellor
Journal:  Front Synaptic Neurosci       Date:  2013-07-30

Review 10.  The pilocarpine model of temporal lobe epilepsy.

Authors:  Giulia Curia; Daniela Longo; Giuseppe Biagini; Roland S G Jones; Massimo Avoli
Journal:  J Neurosci Methods       Date:  2008-04-26       Impact factor: 2.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.